Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy.
Fang P, Pinnix CC, Wu SY, Lee HC, Patel KK, Saini N, Becnel MR, Kaufman G, Thomas SK, Orlowski RZ, Amini B, Lin P, Dabaja BS, Gunther JR. Fang P, et al. Among authors: kaufman g. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):193-199. doi: 10.1016/j.ijrobp.2023.11.039. Epub 2023 Dec 8. Int J Radiat Oncol Biol Phys. 2024. PMID: 38070713
[No title available]
[No authors listed] [No authors listed] PMID: 34700640
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.
Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Kunacheewa C, et al. Br J Haematol. 2021 May;193(3):e23-e26. doi: 10.1111/bjh.17393. Epub 2021 Mar 21. Br J Haematol. 2021. PMID: 33748943 No abstract available.
Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Afrough A, et al. Transplant Cell Ther. 2022 Jun;28(6):307.e1-307.e8. doi: 10.1016/j.jtct.2022.03.020. Epub 2022 Mar 22. Transplant Cell Ther. 2022. PMID: 35331973 Free article.
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. Gaballa MR, et al. Among authors: kaufman gp. Bone Marrow Transplant. 2022 Jul;57(7):1142-1149. doi: 10.1038/s41409-022-01697-4. Epub 2022 May 6. Bone Marrow Transplant. 2022. PMID: 35523847
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Afrough A, et al. Among authors: kaufman gp. Transplant Cell Ther. 2023 Apr;29(4):264.e1-264.e9. doi: 10.1016/j.jtct.2022.05.023. Epub 2022 May 20. Transplant Cell Ther. 2023. PMID: 35605883 Free article.
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis.
Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Shank BR, et al. Among authors: kaufman gp. Clin Lymphoma Myeloma Leuk. 2023 Apr;23(4):279-290. doi: 10.1016/j.clml.2022.12.004. Epub 2022 Dec 10. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36797154 Free PMC article.
SARS-CoV-2 in multiple myeloma: initial observation and management.
Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. Manasanch EE, et al. Leuk Lymphoma. 2020 Nov;61(11):2763-2766. doi: 10.1080/10428194.2020.1780588. Epub 2020 Jun 17. Leuk Lymphoma. 2020. PMID: 33167721 Free PMC article. No abstract available.
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies.
Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Manasanch EE, et al. Among authors: kaufman g. Br J Haematol. 2021 Feb;192(4):e115-e120. doi: 10.1111/bjh.17344. Epub 2021 Jan 24. Br J Haematol. 2021. PMID: 33486754 No abstract available.
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.
Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Gaballa MR, et al. Among authors: kaufman gp. Leuk Lymphoma. 2022 Mar;63(3):710-721. doi: 10.1080/10428194.2021.1992763. Epub 2021 Oct 22. Leuk Lymphoma. 2022. PMID: 34686083
307 results